Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Praxis Precision Medicines (Nasdaq: PRAX) granted inducement restricted stock units on June 1, 2026, under its 2024 Inducement Plan. Awards cover an aggregate 2,754 shares of common stock for thirteen new non-executive employees and were approved under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments, contingent on continued employment.
Positive
- None.
Negative
- None.
News Market Reaction – PRAX
In the Jun 3 session, PRAX gained 8.08%, reflecting a notable positive market reaction. Argus tracked a trough of -14.4% from its starting point during tracking. Our momentum scanner triggered 129 alerts that day, indicating very high trading interest and price volatility. Trading volume was very high at 3.5x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings and update | Positive | -1.4% | Q1 2026 results with cash of $1.4B and multiple NDA milestones. |
| May 05 | Inducement grants | Neutral | +1.4% | RSU grants for 5,420 shares under 2024 Inducement Plan. |
| May 04 | Earnings date, conference | Neutral | -1.3% | Announcement of Q1 call and Bank of America conference appearance. |
| Apr 14 | NDA acceptance | Positive | +8.4% | FDA accepted ulixacaltamide NDA; PDUFA set for Jan 29, 2027. |
| Apr 13 | Clinical data showcase | Positive | +0.3% | Plan to present Phase 3 Essential3 data and multiple sessions at AAN. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News with clearly positive clinical or regulatory tone (e.g., NDA acceptance) has often aligned with positive price moves, while a recent earnings/corporate update saw a mild negative divergence.
Over the last few months, Praxis reported Q1 2026 results and updates on multiple late-stage CNS programs, noting cash of about $1.4 billion and PDUFA dates on September 27, 2026 and January 29, 2027. Positive clinical milestones for ulixacaltamide in Essential Tremor and EMBRAVE data for elsunersen previously coincided with favorable reactions, such as an 8.39% move on FDA NDA acceptance. Routine items like conference participation and earlier inducement grants have produced only modest stock responses, framing today’s small inducement awards as part of regular corporate activity.
Key Terms
restricted stock unit financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on June 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,754 shares of its common stock to thirteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576